A are involved in the pathogenesis of pulmonary hypertension and gestational hypertension through increased smooth muscle proliferation and induction of systemic maternal vascular endothelial cell dysfunction. [20] [21] [22] However, the association between activin A and essential hypertension has not been fully explored.
A recent animal study reported that activin A may cause arterial pressure elevation through effects on the central nervous system. 23 Microinjection of activin A into the paraventricular nucleus caused angiotensin II release which resulted in significant elevation of systemic arterial pressure and mean arterial pressure. 23 The inflammatory and immune modulation characteristics of activin A may play a crucial role in essential hypertension. Therefore, this study aimed to investigate the association between serum activin A levels and systemic arterial pressure.
METHODS AND MATERIALS

Study population
The I-Lan Longitudinal Aging study (ILAS) is a community-based aging cohort study in I-Lan County of Taiwan. 24 The purpose of the ILAS study was to evaluate the complex associations between age, hormones, comorbidities, sarcopenia, and cognitive function. Community-dwelling adults who were 50 years of age or older were randomly selected through the I-Lan county of Taiwan. Selected residents were invited to participate in this study by mail or telephone invitations from the research team and were enrolled only when they fully understood the program and gave their written consent.
The inclusion criteria were: (i) residents who were presently residing in I-Lan county without a plan to move in the future; and (ii) residents aged 50 years or older. The exclusion criteria were: (i) inhabitants who were unable to communicate with the research nurse or grant an interview; (ii) inhabitants who were unable to complete the evaluation tests due to poor functional status; (iii) inhabitants who had limited life expectancy (below 6 months) due to major illnesses; and (iv) current residents of long-term care facilities.
This study was approved by the Institutional Review Board of National Yang Ming University.
Demography, physical examinations, and laboratory examinations
A questionnaire was used to collect demographic information including socioeconomic status, medical history, and smoking habits. Each participant received anthropometric measurements by research nurses, including height, body weight, and waist circumference. The body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. The systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured by using a mercury sphygmomanometer after the subject rested for at least 15 minutes. The average of 3 measurements was used for the analysis.
Blood samples were obtained from every subject the morning after an overnight fast of at least 10 hours. Serum levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, and uric acid were measured by using an automatic analyzer (AVDIA 1800, Siemens, Malvern, PA). Whole blood glycated hemoglobin A1c (HbA1c) was measured by an enzymatic approach using the Tosoh G8 HPLC Analyzer (Tosoh Bioscience, San Francisco, CA). Serum levels of activin A were measured using an enzyme-linked immunosorbent assay kit.
Statistical analysis
Categorical variables were expressed by percentage and descriptive continuous variables were recorded as mean ± SD. Student's t-test was used to compare continuous variables; chi-squared test was used to compare categorical data. One-way analysis of variances was used to compare the difference between 3 tertiles of activin A levels and trend analysis was performed to investigate the ordered relationship. The contribution of each variable was analyzed by Pearson correlation coefficients and the association between activin A levels and blood pressure was analyzed by liner regression models. There was no significant interaction between covariates. All statistical analysis was performed using commercial software (SPSS, IBM Corporation, Armonk, NY). A P value of <0.05 (2 tailed) was considered statistically significant.
RESULTS
A total of 470 participants (50% men, mean age, 69 years) from the ILAS study were eligible for this study. Table 1 summarizes the demographic characteristics of the participants. Among 470 participants, 236 (50.2%) were hypertensive and 234 (49.8%) were normotensive. Hypertensive participants were older, had a higher percentage of diabetes mellitus, higher SBPs, DBPs, pulse pressures (PPs), BMIs, urine albumin to creatinine ratios (UACRs), serum triglyceride levels, uric acid levels, HbA1c, and activin A levels, but had significantly lower total cholesterol levels, lower HDL cholesterol, and lower glomerular filtration rates (GFRs) than those subjects who were normotensive (all P < 0.01).
The clinical and biochemical parameters based on the 3 tertiles (tertile I ≤ 450, 450 < tertile II <564, tertile III ≥ 564 pg/ml) for serum levels of activin A are shown in Table 2 . Participants which had higher activin A levels were older, were more likely to be smokers and were predominantly male. The prevalence of hypertension, SBP, DBP, PP, HbA1c, uric acid levels, and BMI were significantly enhanced with each serum activin A level increment (all P for trend <0.04). Moreover, HDL cholesterol and total cholesterol decreased with each increment of activin A level (all P for trend <0.01). Of note, decreased GFR and increased UACR were observed in subjects with increased activin A levels. Table 3 provides the correlation coefficients among cardiovascular risk factors, arterial blood pressure, and serum activin A levels. Serum activin A levels positively correlated with age, BMI, HbA1c, UA, UACR, SBP, DBP, and PP and negatively correlated with HDL cholesterol, total cholesterol, and GFR (all P < 0.01).
As shown in Table 4 , by multivariate analysis, the association between activin A levels and SBP remained significant after adjusting for age, gender, BMI, UACR, HbA1c, UA, GFR, HDL, TC, and smoking status (P = 0.02, model 3). However, the association between activin A levels and DBP was significant in model 1, but Values are mean ± SD or n (%). Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; HbA1c, glycated hemoglobin A1c; PP, pulse pressure; SBP, systolic blood pressure; UACR, urine albumin to creatinine ratio. Values are mean ± SD or n (%). Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; HbA1c, glycated hemoglobin A1c; PP, pulse pressure; SBP, systolic blood pressure; UACR, urine albumin to creatinine ratio. diminished after accounting for more variables (P = 0.33, model 2; P = 0.29, model 3). After adjustment of multiple variables, activin A level also significantly correlated with PP (P = 0.03, model 3).
DISCUSSION
To the best of our knowledge, the present study was the first to disclose the association between essential hypertension and serum activin A levels. In this study, serum activin A levels were associated with SBP and PP after adjusting for potential confounding factors. Incidentally, we found that increased activin A levels were related to decreased GFRs and elevated UACRs. These novel findings provide evidence that activin A may play a crucial role in the pathogenesis of essential hypertension, blood pressure elevation, and hypertensive-related kidney injury.
Activins are a group of cytokines which were initially named for their activation of follicle-stimulating hormone release within the female reproductive system. Activins belong to the transforming growth factor-β superfamily and share the same pleiotrophic immunoregulation characteristics. Activin A is the first-identified (and most studied) family member. 16 There are 2 main types of activin receptors (ActR1 and ActR2). Binding of activin A to type 1 activin receptor (ActR1B, ALK4) can lead to phosphorylation of the intracellular SMAD proteins 2 and 3, which form a heteromeric transcription factor with SMAD4. Activin A shares common inflammatory and immune regulatory pathways with TGF-β through the SMAD2/3, and was shown to activate an alternative signaling pathway by TRAF6 through downstream MAP kinase, which proves activin A plays a role in the inflammatory response. 16 Owing to their ability to stimulate an inflammatory response, serum concentrations of activin A were associated with different aspects of clinical disease. 9, 10, 12, 13, 25 In the cardiovascular system, elevated serum concentrations of activin A worsen the clinical severity of hemodynamic (cardiac index, LVEDP) and neurohormonal (NT-proBNP) parameters in heart failure patients compared to normal subjects. 14 Moreover, high serum activin A concentrations can cause endothelium dysfunction and vessel remodeling through a break in the balance of vasoactive factors (eNOS, endothelin-1) and an increase in the permeability of endothelium. The consequence of endothelial dysfunction and vessel remodeling may turn into maternal hypertension or pulmonary hypertension. [20] [21] [22] Ge et al. has reported on another pathway by which activin A can affect the cardiovascular system. They injected activin A into the paraventricular nucleus of WKY rats and found a significant increase in downstream signaling transduction Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; GFR, glomerular filtration rate; HDL, high-density lipoprotein; HbA1c, glycated hemoglobin A1c; PP, pulse pressure; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; UA, uric acid; UACR, urine albumin to creatinine ratio.
a Correlation is significant at the 0.01 level (2-tailed). b Correlation is significant at the 0.05 level (2-tailed).
(ActRIIA, SMAD3), release of angiotensin II, and elevation of arterial pressure. 23 Their results suggest that activin A could also increase the arterial pressure not only through a direct effect on the endothelium but also through the central nervous system. However, associations between activin A and essential hypertension has not been well established in humans. As shown in our study, older and hypertensive participants had significantly higher serum levels of activin A. Patients with higher activin A levels also had higher SBPs, DBPs, and PPs. After adjusting various potential confounding factors, serum levels of activin A remained significantly associated with SBP and PP. DBP was associated with levels of activin A significantly under age and gender adjustment. After adjusting all the confounding factors, however, the significance diminished.
The underlying mechanism which governs the association between serum activin A levels and hypertension remains uncertain. According to previous studies, 20-23 the higher serum levels of activin A in older participants may induce endothelial dysfunction through an imbalance in vasoactive factors or an increase in angiotensin II release by the paraventricular nucleus which may contribute, in part, to the pathogenesis of essential hypertension in these participants. This result may partly explain the etiology of essential hypertension, but further studies are needed to verify these findings and clarify the underlying mechanism.
Study limitations
Our study had several limitations. First, we could only report an association between serum levels of activin A and arterial pressure, but the causal relationship remains uncertain due to the cross-sectional study design. Second, our study population was relatively healthy, because we excluded those with any disability. Therefore, our study could not evaluate the role of activin A in sicker patients. The relatively small number of study participants was also one of our limitations. Though the findings of our study demonstrated the association between serum concentrations of activin A, SBP, and PP, further prospective studies are needed to assess whether there is a causal relationship between serum levels of activin A and arterial blood pressure.
In conclusion, our study revealed that serum concentrations of activin A are associated with increased arterial blood pressure and increased PP. This finding may provide further motivation to explore the effects of activin A acts on arterial blood pressure and cardiovascular disease.
